ImmuSAFE Portal

Instructions

  1. Download the “Data Input” and “Sample Manifest” template sheets  here.
  2. Fill in the “Data Input” sheet with the required information from the .GPR files: Slide ID, Block Number, Name, ID/Protein, F635 Median, B635 Median and B635 SD.
  3. Fill in patient specific details in the “Sample Manifest” sheet with the following information: Slide ID, Block number, Sample ID, Date of birth, ID or MRN number, Gender, RT-PCR status, Date of sample collection, Date of sample run, COVID-19 symptoms and Project ID.
    (Note: Please ensure that the Slide ID and Block Number for both sheets match)
  4. Upload the sheets to the ImmuSAFE™ Cloud-based Analysis portal and key in the requested details for report delivery.
  5. An individual report for each sample will be generated and sent to the email address provided in Step 4.

FILE UPLOADER

Description

The ImmuSAFE™ Cloud-based Analysis portal is a fully automated bioinformatics interface designed to analyse and report the sero-positivity of patients against SARS-CoV-2 infection. Readouts from each spot on the array are reported as relative fluorescence units (RFU) which represent the amount of antibody bound to a given protein or protein domain immobilised on the array surface. The platform will analyse and convert the fluorescence readouts from the array into reciprocal values to be reported as binary scores. Sero-positive and sero-negative patients against SARS-CoV-2 infection will be represented as “1” and “0”, respectively.

FEATURED PRODUCTS

IMMUNOME Protein Array

High-throughput multiplexed autoantibody screening protein array containing 1600+
autoantigens

ImmuSAFE COVID Tests

Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza
viruses

SARS-CoV-2 Antigens

7 Recombinant SARS-CoV-2 antigens expressed using the patented KREX™ functional proteomics technology

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics UK Ltd. Registered in England and Wales no. 12889389 | Sengenics Corporation Pte. Ltd. Registered in Singapore no. 201734100D